Core Viewpoint - Passage Bio, Inc. has announced a reverse stock split at a ratio of 1-for-20 to comply with Nasdaq's minimum bid price requirement of $1.00 per share, effective July 14, 2025 [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 62,405,898 to about 3,120,295 [2]. - Proportionate adjustments will be made to the exercise prices and number of shares underlying the Company's equity awards and incentive plans [2]. - The reverse stock split will not change the number of authorized shares or the par value per share [2]. Group 2: Stockholder Information - Registered stockholders holding shares in book-entry form will not need to take action to receive post-split shares [3]. - Stockholders with shares in brokerage accounts will have their positions automatically adjusted, with no action required on their part [3]. - No fractional shares will be issued; stockholders entitled to fractional shares will receive the nearest whole share [3]. Group 3: Company Overview - Passage Bio is a clinical-stage genetic medicines company focused on developing therapies for neurodegenerative diseases [4]. - The lead product candidate, PBFT02, aims to treat conditions like frontotemporal dementia by elevating progranulin levels [4].

Core Points - CLS Holdings USA, Inc. announced a reverse stock split of one post-Consolidation Share for every 4,000,000 pre-Consolidation Shares, approved by 94.27% of Stockholders [1] - The effective date of the Consolidation is set for July 11, 2025, following unanimous approval from the Board of Directors [2] - Stockholders will receive a cash payment of $0.037 per pre-Consolidation Share for any fractional shares resulting from the Consolidation [3] - CLS has applied for voluntary delisting from the Canadian Securities Exchange, with the delisting expected to occur on the same date as the effective date of the Consolidation [4] - CLS Holdings USA Inc. operates as a diversified cannabis company, focusing on integrated cannabis production and retail, utilizing a patented method for cannabinoid extraction [5]

Core Viewpoint - MacKenzie Realty Capital, Inc. has announced a 1-for-10 reverse stock split to increase its share price and meet Nasdaq listing requirements [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will convert ten existing shares into one new share, reducing the total shares outstanding from approximately 15,781,930 to about 1,578,192 [2]. - No fractional shares will be issued; instead, stockholders entitled to a fractional share will receive cash equivalent to the fraction multiplied by the closing price prior to the split [2]. - The effective date of the reverse stock split will be announced at least two business days before implementation [4]. Group 2: Stockholder Information - Stockholders of record will not need to take action to receive post-split shares, as their positions will be automatically adjusted [3]. - Stockholders holding shares through banks or brokers should check with their respective institutions for specific procedures regarding the reverse stock split [3]. Group 3: Company Overview - MacKenzie Realty Capital, founded in 2013, is a West Coast-focused REIT aiming to invest at least 80% of its total assets in real property, with a portfolio consisting of approximately 50% multifamily and 50% boutique class A office properties [5]. - The company has consistently paid dividends since its inception and currently holds interests in 4 multifamily properties and 8 office properties, along with 2 multifamily developments [5].

Core Viewpoint - Cyclacel Pharmaceuticals, Inc. is implementing a 1-for-15 reverse stock split effective July 7, 2025, to enhance its stock price and maintain compliance with Nasdaq listing requirements [1][3]. Company Overview - Cyclacel is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines based on cell cycle, epigenetics, and mitosis biology [4]. - The company is evaluating plogosertib, a PLK1 inhibitor, in patients with solid tumors and hematological malignancies as part of its epigenetic/anti-mitotic program [4]. - Cyclacel aims to build a diversified biopharmaceutical business with a pipeline of novel drug candidates targeting oncology and hematology indications [4]. Reverse Stock Split Details - The reverse stock split will convert every 15 shares of common stock into one share, with no fractional shares issued; any fractions will be rounded to the nearest whole number [2]. - The board of directors and stockholders approved the reverse stock split, which will reduce the number of shares from 23,759,475 to 1,583,965 [3]. - The new CUSIP number for the shares post-split will be 23254L876, and trading will continue under the symbol "CYCC" on The Nasdaq Capital Market [1][3].

Core Viewpoint - Boqii Holding Limited will terminate its Deposit Agreement and implement a reverse stock split, consolidating every 160 ordinary shares into one new ordinary share, with plans to list its Class A ordinary shares on NYSE American LLC [1][2] Company Actions - The termination of the Deposit Agreement was approved by shareholders on June 26, 2025 [1] - A reverse stock split will occur, consolidating every 160 ordinary shares into one new ordinary share [1] - The company plans to list its Class A ordinary shares on NYSE American LLC, replacing the American depositary shares (ADSs) [2] Company Overview - Boqii Holding Limited is a leading pet-focused platform in China, offering a wide selection of high-quality pet products [3] - The company provides products from global leading brands, local emerging brands, and its own private labels, including Yoken, Mocare, and D-cat [3] - Boqii's online sales platforms include Boqii Mall and flagship stores on third-party e-commerce platforms, enhancing customer access and shopping experience [3]

Core Points - The company announced a 1-for-15 reverse stock split effective July 3, 2025, to comply with Nasdaq's minimum bid price requirement [1][2] - The reverse stock split will reduce the number of outstanding shares from approximately 41,492,767 to about 2,766,185 shares [4] - The company entered into a Forbearance Agreement with Bank of America on June 23, 2025, providing additional time to pursue alternative debt financing options [5] Reverse Stock Split Details - The reverse stock split will combine every fifteen shares into one share without changing the par value [3] - No fractional shares will be issued; stockholders will receive whole shares rounded up [3] - The authorized shares will remain unchanged at 250,000,000 shares [4] Forbearance Agreement Insights - The Forbearance Agreement will expire upon the occurrence of certain events, including any Event of Default or breach of the agreement [5] - The company has received two bona fide term sheets from reputable financial institutions for a potential refinancing transaction [5]

Core Viewpoint - Super League Enterprise, Inc. announced a reverse stock split at a ratio of 1-for-40 to comply with Nasdaq's minimum bid price requirement for continued listing [1][4]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 12:01 AM on June 23, 2025, with shares trading on a split-adjusted basis on the same day [2]. - The number of outstanding shares will decrease from approximately 35.4 million to about 884 thousand shares following the split [3]. - Each stockholder's percentage ownership and voting power will remain largely unchanged, with fractional shares rounded up to the nearest whole share [5]. Group 2: Compliance and Listing - The reverse split is a response to a deficiency notice from Nasdaq regarding the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) [4]. - The company aims to regain compliance with Nasdaq's continued listing standards through this action [9]. Group 3: Company Overview - Super League is a leader in engaging audiences through playable media and experiences within mobile games and immersive platforms [7]. - The company provides global brands with interactive ads and content, enhancing consumer engagement and brand loyalty [7].

Core Viewpoint - Unicycive Therapeutics, Inc. is implementing a 1-for-10 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective June 18, 2025, with trading on a split-adjusted basis starting June 20, 2025 [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will combine every ten shares into one, reducing the number of issued shares from approximately 126,409,281 to about 12,640,929 [4]. - Stockholders will not receive fractional shares; instead, fractional interests will be rounded up to the next whole share [3]. - The reverse stock split will not affect stockholders' percentage ownership or voting power, except for minor changes due to fractional shares [3]. Group 2: Compliance and Adjustments - The reverse stock split aims to increase the bid price of the common stock to meet the $1.00 minimum bid price requirement for continued listing on Nasdaq [2]. - Proportionate adjustments will be made to the exercise prices and number of shares underlying stock options, warrants, and preferred stock as a result of the reverse stock split [5]. Group 3: Company Overview - Unicycive Therapeutics is focused on developing therapies for kidney diseases, with its lead investigational treatment, oxylanthanum carbonate, under FDA review for treating hyperphosphatemia in chronic kidney disease patients on dialysis [8]. - The second investigational treatment, UNI-494, is aimed at conditions related to acute kidney injury and has received orphan drug designation from the FDA [9].

Group 1 - KULR Technology's stock experienced a significant decline of 21.3% on a trading day when the S&P 500 was up 0.9% [1] - The decline is attributed to a valuation pullback following the announcement of an 8-for-1 reverse stock split set to take effect on June 23 [2][6] - Year-to-date, KULR's share price has dropped approximately 74.5%, falling below the $1 threshold required for continued trading on the NYSE-American Market [4] Group 2 - The reverse stock split is intended to boost the share price without changing the company's fundamentals, which may help KULR avoid stricter NYSE rules regarding reverse splits [5][6] - While continuing to trade on the NYSE-American Market is beneficial for long-term accessibility to investors, the negative reaction from some investors is understandable, as reverse splits can signal struggles and limit potential short-term gains [7]

Core Viewpoint - Onconetix, Inc. has received approval from the Nasdaq Hearings Panel for continued listing on The Nasdaq Stock Market, contingent upon compliance with specific Nasdaq Listing Rules by set deadlines [1][2]. Group 1: Compliance and Listing Status - On June 11, 2025, Onconetix was granted a decision for continued listing, requiring compliance with the Periodic Filing Listing Rule by June 13, 2025, and the Bid Price Listing Rule by June 30, 2025 [1]. - The company demonstrated compliance with the Periodic Filing Listing Rule on June 12, 2025, by filing the Form 10-Q for the period ended March 31, 2025 [2]. - A 1-for-85 reverse stock split of its outstanding shares was completed on June 13, 2025, to help meet listing requirements [2]. Group 2: Company Overview - Onconetix, Inc. is a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology [3]. - The company owns Proclarix, an in vitro diagnostic test for prostate cancer, which is approved for sale in the European Union [3].